Work

Patient with perianal fistulizing Crohn's disease and failure to intensified risankizumab treatment.

Year: 2026

Type: article

Abstract: No direct evidence for the management of perianal fistulizing Crohn's disease following risankizumab treatment failure was identified. Alternative therapies, such as ustekinumab or vedolizumab, may be considered based on indirect evidence, but further research is necessary to establish specific guidelines.

Source: Zenodo (CERN European Organization for Nuclear Research)

DOI: 10.5281/zenodo.23730066

Author: Tripdatabase

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7224124758

FWCI:

Cites:

Cited by:

Related to: 10